2024 Atlantic Regional Hematopathology Meeting

Advancements in hematopathology based on molecular and genetic information are rapidly evolving, making it challenging to keep up with the latest developments and their implications for diagnosis and therapy. This meeting will focus on the role of molecular pathology and new technologies in diagnosis, prognostic stratification, and treatment of complex cases. Participants will gain insights into the significant changes, revisions, and new categories in the 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors. Renowned invited pathologists and senior authors of the new WHO edition, Dr. Joseph Khoury, Dr. German Ott, and Dr. Sanam Loghavi, will discuss notable updates, modifications, and new classifications in the morphology and molecular genetics of hematologic neoplasms that can be immediately applied in practice.

May 11, 2024
8:25 am – 3 pm
Fox Chase Cancer Center Leidy Auditorium
333 Cottman Avenue, Philadelphia

Complimentary registration for all participants; includes breakfast, lunch, coffee breaks, and program

Hematopathologists, pathologists of other subspecialties, hematologists/oncologists, radiation oncologists, internists, primary care providers, fellows and residents of pathology, oncology, and other specialties

Lucía Tono, PhD, JD, MEd
215-728-3797 | Lucia.Tono-Ramirez@tuhs.temple.edu

For attendees looking for overnight accommodations on May 10 – 11, a limited number of rooms are available at the Philadelphia Marriott Old City (located at One Dock Street, Philadelphia) at a rate of $239 (plus taxes and fees).

To make a reservation, call 800-228-9290 and ask for the Fox Chase Cancer Center group. Reservation deadline is April 11, 2024.

At the end of this activity, participants should be able to:

  • Recognize the indicators/markers and molecular tests to look for in complex cases to aid in diagnosis
  • When appropriate, incorporate recent molecular, immunophenotypic, and genetic information when interpreting results, determining diagnoses, and selecting therapies
  • Discuss the latest advances related to the characteristics of hematopoietic malignancies


Joseph Khoury, MD
Professor and Chair
Department of Pathology and Microbiology
University of Nebraska Medical Center


German Ott, MD
and Head
Department of Clinical Pathology
Robert-Bosch Krankenhaus
Stuttgart, Germany



Sanam Loghavi, MD
Department of Hematopathology MD Anderson Cancer Center



Reza Nejati, MD
Associate Professor
Medical Director of TUHS – FCCC Clinical Laboratories
Director, Flow Cytometry Lab Department of Pathology
Fox Chase Cancer Center


Mariusz Wasik, MD
Professor & Chair of Pathology
Associate Director of Cancer Center DE&S Morel
S&S Bayster Chair
in Molecular Diagnostics
Fox Chase Cancer Center

Nicholas Mackrides, MD
Assistant Professor
Department of Pathology
Fox Chase Cancer Center

Tahseen I. Al-Saleem, MD
Professor Emeritus
Department of Pathology
Fox Chase Cancer Center

Henry C. Fung, MD, FACP, FRCPE
Department of Bone Marrow Transplant and Cellular Therapies
Fox Chase Cancer Center

We invite you to submit abstracts of clinical, scientific, and educational value with a focus on the role of molecular pathology and new technologies in the diagnosis, prognostic stratification, and treatment of challenging cases.

To submit an abstract for consideration, please send the following by April 1, 2024 to lucia.tono-ramirez@tuhs.temple.edu:

  1. Two-page abstract (maximum 1000 words); please structure your case as follows: clinical information, case description, proposed diagnosis, interesting features of case in Word (NO SLIDES).
  2. In the abstract, please specify the name, credential, affiliation, and e-mail of the person who will be presenting the case if selected for platform presentation

Priority will be given to early abstract submissions. Notifications of cases selected for platform and poster presentation will be via e-mail.

If you are selected for PLATFORM PRESENTATION, please follow these instructions:

Platform presentations consist of a 15-minute lecture.

You will receive an email from “eeds” (the CME software) asking you to upload the following by April 29, 2024 (please follow the prompts):

  1. Electronic copy of your PowerPoint slides as you will present them. Please title your slides as follows: “Presenter’s last name, first initial–Title”
  2. Speaker disclosure of the person presenting the case If you are selected for POSTER EXHIBIT, please follow these instructions:

You will receive an email from “eeds” (the CME software) asking you to upload the following by April 29, 2024 (please follow the prompts):

  1. Electronic copy of your poster

Please bring a hard copy of your poster on the day of the event—we will have 4’x 6’ poster boards with stands available.

Poster exhibits will be displayed all day and can be presented during breaks.

This year’s meeting will introduce our first Atlantic Regional Hematopathology Meeting Presentation Awards. The judgment of the presentations will be based on the document submitted by end of day April 29, 2024. The first author of the best presentation in each category will be recognized at the conclusion of the meeting for the following awards:

  • Best platform presentation award: $1,000
  • Best poster presentation award: $1,000


The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians.

The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity.

It is the policy of the Temple Health Office for Continuing Medical Education to ensure that all sponsored continuing medical education activities are independently designed and produced and include content that is valid, objective, balanced, free of commercial bias, and in the best interest to the public. Temple Health policy requires everyone in a position to control the content of an educational activity to disclose all financial relationships with ineligible companies and to disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Temple Health Office for Continuing Medical Education has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity.


February 6, 2024


May 27, 2024